CRISPR Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director George Simeon
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 10-K: Annual report
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth
CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 424B5: Prospectus
CRISPR Therapeutics | 8-K: Current report
No Data